Aurora Cannabis (NASDAQ: ACB) acquires Safari Flower in $26.5M EU GMP deal
Rhea-AI Filing Summary
Aurora Cannabis Inc. has acquired Safari Flower Company for aggregate consideration valued at $26.5 million. The deal includes 2,417,180 common shares, $15 million in cash at closing, and an additional $2 million cash payment contingent on certain conditions.
Safari Flower operates a 59,000 square foot EU GMP certified indoor cultivation and manufacturing facility in Ontario, which will add tightly aligned capacity to Aurora’s existing network. Aurora plans to use this expanded EU GMP capacity to supply high-margin international medical cannabis markets such as Germany, Australia, Poland, and the UK.
The company expects the acquisition to contribute positively to Adjusted EBITDA in fiscal year 2027, with incremental benefits in fiscal 2028 and beyond as operations are optimized, leveraging Aurora’s plant science and operational expertise.
Positive
- None.
Negative
- None.
Insights
Aurora adds EU GMP capacity with a $26.5M Safari Flower acquisition.
Aurora Cannabis is buying Safari Flower Company for aggregate consideration of $26.5 million, combining cash and shares plus a contingent cash component. The acquired 59,000 square foot EU GMP certified Ontario facility is intended to integrate with Aurora’s existing cultivation and manufacturing footprint.
The company plans to channel this new capacity into international medical markets, including Germany, Australia, Poland and the UK, which it characterizes as high-margin and highly regulated. Management states the transaction is expected to deliver positive Adjusted EBITDA in fiscal year 2027, with incremental benefits in 2028 and beyond as the assets are optimized.
Overall impact will depend on execution, integration, and demand in Aurora’s export markets. Subsequent financial disclosures for fiscal 2027 and 2028 will show whether the projected positive Adjusted EBITDA contributions and operational efficiencies from this acquisition are realized.
Key Figures
Key Terms
EU GMP certified technical
Adjusted EBITDA financial
Non-GAAP Measures financial
forward-looking statements regulatory
customary adjustments financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File No. 001-38691
AURORA
CANNABIS INC.
(Translation of registrant's name into English)
2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐ Form 40-F ☒
SUBMITTED HEREWITH
| Exhibits | Description | |
| 99.1 | News release dated April 15, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Miguel Martin
Miguel Martin
Chief Executive Officer
Date: April 15, 2026
Exhibit 99.1
Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets
NASDAQ | TSX: ACB
EDMONTON, AB, April 15, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction").
"The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market. We intend to leverage our extensive plant science and operational expertise to increase the supply of high quality, EU GMP manufactured flower that further enhances our leadership in these expanding, high margin and highly regulated markets. An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide," said Miguel Martin, Executive Chairman and Chief Executive Officer for Aurora.
Strategic Rationale
- Safari Flower Company's 59,000 square foot, purpose-built EU GMP certified indoor cultivation and manufacturing facility in Ontario, Canada will provide the Company with incremental capacity that is closely aligned with its existing cultivation and manufacturing sites.
- The increased capacity will be used to supply EU GMP flower to Aurora's key international markets, including Germany, Australia, Poland, and the UK, and support further market expansion.
- This transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond as these assets are optimised within the Company's supply network.
- Aurora intends to leverage its plant science and operational expertise to realize operational efficiencies, improve cultivation yields and support commercial execution in the high margin international markets.
Transaction Details
Aurora, through a wholly-owned subsidiary, indirectly purchased 100% of the shares of 9869247 Canada Limited ("Safari Flower Company") for aggregate consideration valued at $26.5 million, inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions. As consideration on closing, Aurora (i) issued the selling shareholder 2,417,180 common shares; and (ii) paid the selling shareholder $15 million in cash, subject to customary adjustments post-closing.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the Transaction, including, but not limited to: the impact of the Transaction on the Company's financial performance and the synergies, revenue, positive cash flow and positive Adjusted EBITDA expected to be realized as a result of the Transaction.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry , and assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Non-GAAP Measures
This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed
"Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis
and cannabis companies. Non-GAAP Measures in this news release include, but are not limited to, Adjusted EBITDA. Non-GAAP Measures
should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating
results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended
to provide additional information and to assist management and investors in assessing financial performance and should not be considered
in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading
"Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis
for the three and nine months ended December 31, 3025, and 2025 (the "MD&A") is incorporated by reference into this
news release. The MD&A is available on the Company's issuer profile on SEDAR+ at www.sedarplus.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-accelerates-global-medical-cannabis-leadership-with-accretive-acquisition-of-safari-flower-company-expanding-eu-gmp-capacity-to-serve-growing-high-margin-international-markets-302742337.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2026/15/c4161.html
%CIK: 0001683541
For further information: For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 07:05e 15-APR-26